ixabepilone ixabepilone ixabepilone (inn; also known as azaepothilone b, codenamed bms-247550) is a pharmaceutical drug developed by bristol-myers squibb as a chemotherapeutic medication for cancer. ixabepiloneclinical datatrade namesixempraother namesazaepothilone bahfs/drugs.commonographmedlineplusa608042license data us fda: ixabepilone routes ofadministrationintravenous infusionatc codel01dc04 (who) legal statuslegal status us: ℞-only pharmacokinetic databioavailabilityn/aprotein binding67 to 77%metabolismextensive, hepatic, cyp3a4-mediatedelimination half-life52 hoursexcretionfecal (mostly) and renalidentifiers iupac name (1r,5s,6s,7r,10s,14s,16s)-6,10-dihydroxy-1,5,7,9,9-pentamethyl-14--17-oxa-13-azabicycloheptadecane-8,12-dione cas number219989-84-1 npubchem cid6445540iuphar/bps6824drugbankdb04845 ychemspider20145579 yuniik27005np0akeggd04645 ychemblchembl1201752 ncomptox dashboard (epa)dtxsid70870252 echa infocard100.158.736 chemical and physical dataformulac27h42n2o5smolar mass506.70 g·mol−13d model (jsmol)interactive image smiles cc3nc(/c=c(\c)1c2o2(c)ccc(c)(o)(c)c(=o)c(c)(c)(o)cc(=o)n1)cs3 inchi inchi=1s/c27h42n2o5s/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32h,8-10,12-13h2,1-7h3,(h,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1 ykey:fabufpqfxzvhfb-pvynadrnsa-n y ny (what is this?) (verify) history ixabepilone is a semi-synthetic analog of epothilone b, a natural chemical compound produced by sorangium cellulosum. epothilone b itself could not be developed as a pharmaceutical drug because of poor metabolic stability and pharmacokinetics. ixabepilone was designed through medicinal chemistry to improve upon these properties. pharmacology much like taxol, ixabepilone acts to stabilize microtubules. it is highly potent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to taxane type drugs. approval on october 16, 2007, the u.s. food and drug administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. in november 2008, the emea has refused a marketing authorisation for ixabepilone. ixabepilone is administered through injection, and is marketed under the trade name ixempra. clinical uses ixabepilone, in combination with capecitabine, has demonstrated effectiveness in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. it has been investigated for use in treatment of non-hodgkin's lymphoma. in pancreatic cancer phase two trial it showed some promising results (used alone). combination therapy trials are ongoing.